Cargando…
The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826061/ https://www.ncbi.nlm.nih.gov/pubmed/35155458 http://dx.doi.org/10.3389/fmed.2021.707895 |
_version_ | 1784647353115869184 |
---|---|
author | Ma, Tengfei Wiggins, Chad C. Kornatowski, Breanna M. Hailat, Ra'ed S. Clayburn, Andrew J. Guo, Winston L. Johnson, Patrick W. Senefeld, Jonathon W. Klassen, Stephen A. Baker, Sarah E. Bruno, Katelyn A. Fairweather, DeLisa Wright, R. Scott Carter, Rickey E. Li, Chenxi Joyner, Michael J. Paneth, Nigel S. |
author_facet | Ma, Tengfei Wiggins, Chad C. Kornatowski, Breanna M. Hailat, Ra'ed S. Clayburn, Andrew J. Guo, Winston L. Johnson, Patrick W. Senefeld, Jonathon W. Klassen, Stephen A. Baker, Sarah E. Bruno, Katelyn A. Fairweather, DeLisa Wright, R. Scott Carter, Rickey E. Li, Chenxi Joyner, Michael J. Paneth, Nigel S. |
author_sort | Ma, Tengfei |
collection | PubMed |
description | Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients. |
format | Online Article Text |
id | pubmed-8826061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88260612022-02-10 The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma Ma, Tengfei Wiggins, Chad C. Kornatowski, Breanna M. Hailat, Ra'ed S. Clayburn, Andrew J. Guo, Winston L. Johnson, Patrick W. Senefeld, Jonathon W. Klassen, Stephen A. Baker, Sarah E. Bruno, Katelyn A. Fairweather, DeLisa Wright, R. Scott Carter, Rickey E. Li, Chenxi Joyner, Michael J. Paneth, Nigel S. Front Med (Lausanne) Medicine Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients. Frontiers Media S.A. 2022-01-26 /pmc/articles/PMC8826061/ /pubmed/35155458 http://dx.doi.org/10.3389/fmed.2021.707895 Text en Copyright © 2022 Ma, Wiggins, Kornatowski, Hailat, Clayburn, Guo, Johnson, Senefeld, Klassen, Baker, Bruno, Fairweather, Wright, Carter, Li, Joyner and Paneth. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Ma, Tengfei Wiggins, Chad C. Kornatowski, Breanna M. Hailat, Ra'ed S. Clayburn, Andrew J. Guo, Winston L. Johnson, Patrick W. Senefeld, Jonathon W. Klassen, Stephen A. Baker, Sarah E. Bruno, Katelyn A. Fairweather, DeLisa Wright, R. Scott Carter, Rickey E. Li, Chenxi Joyner, Michael J. Paneth, Nigel S. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma |
title | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma |
title_full | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma |
title_fullStr | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma |
title_full_unstemmed | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma |
title_short | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma |
title_sort | role of disease severity and demographics in the clinical course of covid-19 patients treated with convalescent plasma |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826061/ https://www.ncbi.nlm.nih.gov/pubmed/35155458 http://dx.doi.org/10.3389/fmed.2021.707895 |
work_keys_str_mv | AT matengfei theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT wigginschadc theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT kornatowskibreannam theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT hailatraeds theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT clayburnandrewj theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT guowinstonl theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT johnsonpatrickw theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT senefeldjonathonw theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT klassenstephena theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT bakersarahe theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT brunokatelyna theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT fairweatherdelisa theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT wrightrscott theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT carterrickeye theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT lichenxi theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT joynermichaelj theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT panethnigels theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT matengfei roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT wigginschadc roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT kornatowskibreannam roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT hailatraeds roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT clayburnandrewj roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT guowinstonl roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT johnsonpatrickw roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT senefeldjonathonw roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT klassenstephena roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT bakersarahe roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT brunokatelyna roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT fairweatherdelisa roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT wrightrscott roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT carterrickeye roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT lichenxi roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT joynermichaelj roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma AT panethnigels roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma |